Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 16:50
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
Get a lifetime subscription to this time-saving AI writing tool for under £30
US power grids vulnerable to extreme heat conditions this summer - NERC
How tall is Pokimane? Exploring Twitch queen's height compared to rumored boyfriend Kevin Kim
Apple may have leaked the name of its mixed reality operating system
Andrew Tate accuses Adin Ross and Kai Cenat of 'streaming garbage', asks fans to 'become better' during 'Emergency Meeting' podcast
Watch German Netflix for free with this simple hack
Sam Bankman-Fried's trial to resume with testimony from ex-FTX executive
Why did Paige Spiranac hit out at Jay Monahan amid PGA Tour-LIV Golf merger? 'You can wear shorts now'